ADMA ADMA Biologics, Inc.
Healthcare$8.15-1.09%ClosedMarket Cap: $1.89B
As of 2026-05-26
Valuation
P/E (TTM)
15.72
PEG
—
P/B
4.98
P/S
3.75
EV/EBITDA
9.29
DCF Value
$-117.09
FCF Yield
5.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.3%
Operating Margin
40.6%
Net Margin
32.4%
ROE
39.0%
ROA
24.9%
ROIC
27.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $114.5M | 70.5% | $50.3M | $45.3M | $— | — |
| Q4 null | $139.2M | 63.8% | $62.8M | $49.4M | $— | — |
| FY null | $510.2M | 57.4% | $191.4M | $146.9M | $— | — |
| Q3 null | $134.2M | 56.3% | $51.0M | $36.4M | $— | — |
| Q2 null | $122.0M | 55.1% | $42.8M | $34.2M | $— | — |
| Q1 null | $114.8M | 53.2% | $34.9M | $26.9M | $— | — |
| Q4 null | $117.5M | 53.9% | $38.3M | $111.9M | $— | — |
| FY null | $426.5M | 51.5% | $139.0M | $197.7M | $— | — |
| Q3 null | $119.8M | 49.8% | $39.6M | $35.9M | $— | — |
| Q2 null | $107.2M | 53.6% | $39.2M | $32.1M | $— | — |
| Q1 null | $81.9M | 47.8% | $21.8M | $17.8M | $— | — |
| Q4 2023 | $73.9M | 42.1% | $14.2M | $-17.6M | $-0.08 | — |